Eli Lilly’s orforglipron outshines oral semaglutide in landmark diabetes trial

The results, published in The Lancet, showed orforglipron delivered significantly greater reductions in both A1C and body weight across primary and key secondary endpoints

Lilly breakthrough: Dual treatment clears skin & cuts weight in psoriasis patients

The trial targeted a patient population with high BMI and extensive skin involvement, averaging over 39 kg/m²

Indian pharma market grew 10.2% yoy in January 2026

Ind-Ra expects chronic therapies to outpace IPM as compliance improves and lifestyle diseases rise

Centivax launches first human trial of universal flu vaccine

Roche BTK drug emerges as potential breakthrough in primary progressive MS

Sai Life Sciences posts stellar Q3, revenue surges 27% YoY; PAT nearly doubles

Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26

Aicuris’ Pritelivir delivers Phase 3 win in hard-to-treat herpes patients

The PRIOH-1 study met its primary endpoint, delivering statistically significant and clinically meaningful improvements in lesion healing

Pfizer’s monthly obesity drug shows breakthrough weight loss in Phase 2b trial

The study tested whether PF’3944 could maintain efficacy when switching from weekly to monthly injections and remain safe and well-tolerated

Zydus Wellness net sales up by 113.7% in Q3 FY26

Glucon-D maintained its leadership position with a 59% MAT market share

Glenmark reports robust Q3 FY26 performance, revenues surge 15% YoY

rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million